BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Foley RN, Curtis BM, Parfrey PS. Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy. Clin J Am Soc Nephrol 2008;3:1669-75. [PMID: 18922988 DOI: 10.2215/CJN.02100508] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Brenner N, Kommalapati A, Ahsan M, Ganguli A. Red cell transfusion in chronic kidney disease in the United States in the current era of erythropoiesis stimulating agents. J Nephrol 2020;33:267-75. [PMID: 31782127 DOI: 10.1007/s40620-019-00680-5] [Reference Citation Analysis]
2 Foley RN. Treatment of anemia in chronic kidney disease: known, unknown, and both. J Blood Med 2011;2:103-12. [PMID: 22287869 DOI: 10.2147/JBM.S13066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Toida T, Iwakiri T, Sato Y, Komatsu H, Kitamura K, Fujimoto S. Relationship between Hemoglobin Levels Corrected by Interdialytic Weight Gain and Mortality in Japanese Hemodialysis Patients: Miyazaki Dialysis Cohort Study. PLoS One 2017;12:e0169117. [PMID: 28046068 DOI: 10.1371/journal.pone.0169117] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
4 Song HY, Wei CM, Zhou WX, Hu HF, Wan QJ. Association between admission hemoglobin level and prognosis in patients with type 2 diabetes mellitus. World J Diabetes 2021; 12(11): 1917-1927 [PMID: 34888016 DOI: 10.4239/wjd.v12.i11.1917] [Reference Citation Analysis]
5 Coronado Daza J, Martí-Carvajal AJ, Ariza García A, Rodelo Ceballos J, Yomayusa González N, Páez-Canro C, Loza Munárriz C, Urrútia G. Early versus delayed erythropoietin for the anaemia of end-stage kidney disease. Cochrane Database Syst Rev 2015;:CD011122. [PMID: 26671531 DOI: 10.1002/14651858.CD011122.pub2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
6 Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, Wiebe N, Strippoli GF. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane Database Syst Rev 2014;:CD010590. [PMID: 25486075 DOI: 10.1002/14651858.CD010590.pub2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
7 Hiremath S, Holden RM, Fergusson D, Zimmerman DL. Antiplatelet medications in hemodialysis patients: a systematic review of bleeding rates. Clin J Am Soc Nephrol 2009;4:1347-55. [PMID: 19578002 DOI: 10.2215/CJN.00810209] [Cited by in Crossref: 56] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
8 Hahn D, Cody JD, Hodson EM. Frequency of administration of erythropoiesis-stimulating agents for the anaemia of end-stage kidney disease in dialysis patients. Cochrane Database Syst Rev 2014;:CD003895. [PMID: 24872328 DOI: 10.1002/14651858.CD003895.pub3] [Cited by in Crossref: 6] [Article Influence: 0.8] [Reference Citation Analysis]
9 Foley RN, Curtis BM, Parfrey PS. Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a randomized trial. Clin J Am Soc Nephrol 2009;4:726-33. [PMID: 19339412 DOI: 10.2215/CJN.04950908] [Cited by in Crossref: 45] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
10 . Chapter 3: Use of ESAs and other agents to treat anemia in CKD. Kidney Int Suppl (2011) 2012;2:299-310. [PMID: 25018950 DOI: 10.1038/kisup.2012.35] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
11 Zhang Y, Ren S, Xue H, Wang AY, Zou Y, Cai Y, He J, Yuan X, Jiang F, Wei J, Yang D, He D, Hu S, Lei M, Deng F, Chen J, Wang X, He Q, Li G, Hong D. Roxadustat in treating anemia in dialysis patients (ROAD): protocol and rationale of a multicenter prospective observational cohort study. BMC Nephrol 2021;22:28. [PMID: 33441103 DOI: 10.1186/s12882-021-02229-w] [Reference Citation Analysis]
12 Ye Y, Liu H, Chen Y, Zhang Y, Li S, Hu W, Yang R, Zhang Z, Lv L, Liu X. Hemoglobin targets for the anemia in patients with dialysis-dependent chronic kidney disease: a meta-analysis of randomized, controlled trials. Ren Fail 2018;40:671-9. [PMID: 30741617 DOI: 10.1080/0886022X.2018.1532909] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
13 Dmitrieva O, de Lusignan S, Macdougall IC, Gallagher H, Tomson C, Harris K, Desombre T, Goldsmith D. Association of anaemia in primary care patients with chronic kidney disease: cross sectional study of quality improvement in chronic kidney disease (QICKD) trial data. BMC Nephrol. 2013;14:24. [PMID: 23351270 DOI: 10.1186/1471-2369-14-24] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]